PCSK9 and metabolic syndrome: As research continues to unravel the full potential of PCSK9 inhibitors, their role in reducing cardiovascular risk is likely to be further refined, ultimately enhancing long-term outcomes and the overall well-being of patients with dyslipidemia and CVD.